FDA Determines Regulatory Review Period for PREVYMIS IV Solution Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially set a review period for a patent extension application related to PREVYMIS IV Solution, a new drug application submitted to the agency, following a request from the U.S. Patent and Trademark Office (USPTO)